EU won't take up option to buy more Astrazeneca vaccines

The EU has opted out of buying more vaccine doses from Astrazeneca and instead plans to buy vaccines from Pfizer/Biontech, since the latter company has better met the demands of its contract, and since its vaccine type has less severe side effects than those possibly connected with the Astrazeneca vaccine.



The EU will not be making use of its contractual option to buy 100 million more vaccine doses from Astrazeneca, according to an EU spokesman for the EU Commission at a press conference in Bruxelles.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Latest news

See all jobs